<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/integrated-process-solutions-for-modern-manufacturing</loc>
    <lastmod>2026-10-01T14:48:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Integrated Process Solutions for Modern Manufacturing</news:title>
      <news:keywords>Dec Group process solutions, pharmaceutical manufacturing automation, integrated process engineering, Frederic Dietrich Dec Group, powder handling to aseptic filling</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/Image(87)20261001144236.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lilly-retatrutide-phase-3-weight-loss-diabetes-trial</loc>
    <lastmod>2026-10-01T13:57:02+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Lilly Retatrutide Phase 3 Trial Yields 20.8% Diabetes Weight Loss</news:title>
      <news:keywords>Lilly Retatrutide</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/c34887b9-5401-4a7f-be50-65e326268175.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/roche-fda-priority-review-fenebrutinib-multiple-sclerosis</loc>
    <lastmod>2026-10-01T13:57:03+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Roche Fenebrutinib Gets FDA Priority Review In Two MS Indications</news:title>
      <news:keywords>Roche</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/a06341b4-1c75-4df3-a29c-74c1fffeb08c.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/acrotech-biopharma-launches-adquey-us-dermatology-fda-approval</loc>
    <lastmod>2026-10-01T13:56:36+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Acrotech Launches Topical PDE4 Inhibitor ADQUEY In US Via FDA Nod</news:title>
      <news:keywords>Acrotech</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/d39d53cf-fef7-4b37-ac88-25394e273aee.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/shilpa-biologicals-launches-sb-himax-platform-biologics-development</loc>
    <lastmod>2026-10-01T13:56:33+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Shilpa Biologicals Launches SB HiMax Biologics Speed Platform</news:title>
      <news:keywords>Shilpa Biologicals</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/18cff367-1437-45d2-b5a5-1fbeb063770b.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lilly-zepbound-superior-weight-loss-wegovy-hd-72-week-analysis</loc>
    <lastmod>2026-10-01T13:58:27+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Lilly Zepbound Beats Wegovy HD Weight Loss In 72-Week Trial</news:title>
      <news:keywords>Lilly Zepbound</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/91c419e3-2669-4143-ad9a-b456625c483f.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/sanofi-regeneron-expand-alliance-long-acting-immunology-antibodies</loc>
    <lastmod>2026-10-01T13:56:36+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Sanofi And Regeneron Expand Immunology Alliance In $8B Grand Deal</news:title>
      <news:keywords>Sanofi</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/259ac5d0-2b53-4b76-a3fd-d3e7f4eef8ea.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/roche-giredestrant-evera-phase-iii-pfs-dual-pdufa-2026</loc>
    <lastmod>2026-10-01T13:59:37+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Roche Phase III PFS Gains Hits Ahead Of Dual 2026 PDUFA Deadlines</news:title>
      <news:keywords>Roche</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/ddac86bd-769e-43a7-b9da-895be0fa310c.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/regeneron-sanofi-alliance-expansion-long-acting-immunology-antibodies-2026</loc>
    <lastmod>2026-10-01T14:03:50+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Regeneron &amp; Sanofi Sign $8B Expansion For Four Long Antibodies</news:title>
      <news:keywords>Regeneron</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/277435a3-6cec-42be-8c7d-40ff0e1edefc.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-domperidone-expanded-access-supply-closure-ind-importation</loc>
    <lastmod>2026-10-01T14:06:22+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Ends Domperidone Access Supply; New IND Import Path Open</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/97d1b49c-b8ee-44f0-bd8b-aa38dce1461d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-zumilokibart-phase-2-atopic-dermatitis</loc>
    <lastmod>2026-10-01T14:03:47+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Abbvie Zumilokibart Meets Easi 75; Key Cmc Qa Phase Three Roadmap</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/c8759238-082b-40ff-92a5-7b6f3dbbccb7.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/zealand-pharma-survodutide-phase-iii-synchronize-2-weight-loss-type-2-diabetes</loc>
    <lastmod>2026-10-01T14:10:40+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Zealand Survodutide Gains 13.1% Weight Loss In Phase 3 Trial</news:title>
      <news:keywords>Zealand Survodutide</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/e2052693-d301-4309-822d-7a1f9d1803dd.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-refreshes-drug-interaction-guidance-index-m12-october-2024-labeling</loc>
    <lastmod>2026-10-01T14:10:39+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Refreshes M12 Drug Interaction And Oct Labeling Index</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/69cd8e88-0157-4306-b299-79603844e459.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/boehringer-ingelheim-survodutide-phase-iii-synchronize-2-weight-loss-results</loc>
    <lastmod>2026-10-01T13:57:03+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Boehringer Survodutide Shows 13.1% Weight Loss In Phase III Trial</news:title>
      <news:keywords>Boehringer Survodutide</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/d5e21fe1-beec-4d8a-8d99-4b080026b68f</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-biopharmaceutical-manufacturing-fellowship-curia-global-office-pharmaceutical-quality</loc>
    <lastmod>2026-10-01T14:12:44+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Biotech Fellowship Places Fellows At Curia And OPQ Office</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/cb45aa56-b9ff-4dbf-ba00-08018c2b8f93.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-cder-guidance-taxonomy-cmc-cgmp-ich-quality-categories</loc>
    <lastmod>2026-10-01T14:14:27+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Publishes Updated CDER Guidance On CMC, CGMP, And ICH</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/07a103a6-3d62-4790-9d56-e7b6ee4e4c99.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/bristol-myers-squibb-fda-approval-camzyos-pediatric-ohcm</loc>
    <lastmod>2026-10-01T10:44:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Bristol Myers Squibb Camzyos Wins Fda Approval For Pediatric Ohcm</news:title>
      <news:keywords>Bristol Myers</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/f5d2e618-9277-4403-937c-b196cc5287a6.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-updates-biological-product-deviation-codes-cber-reporting</loc>
    <lastmod>2026-10-01T10:44:12+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates Biological Product Deviation Codes For Cber Reporting</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/c2f1eb47-36b2-4595-9c8b-07cf876ac4ae.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/tapi-appoints-serge-rogasik-ceo-cdmo-growth-supply-chain</loc>
    <lastmod>2026-10-01T10:44:03+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>Tapi Appoints Serge Rogasik As Ceo To Drive Cdmo Growth Expansion</news:title>
      <news:keywords>Tapi</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/fd3f1b14-47a6-4f7f-bdb2-f93e7c6727b2</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-updates-biosimilars-action-plan-bsufa-iii</loc>
    <lastmod>2026-10-01T10:49:37+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates Biosimilars Action Plan To Align With Bsufa Iii Goals</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/b71cb7c1-60d4-4a01-82ec-79d8bbfc0d7d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-e2br3-icsr-submission-toolkit-xml-schema-aems-regional-guide</loc>
    <lastmod>2026-10-01T10:47:33+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Consolidates E2b Icsr Submission Toolkit With Regional Guides</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/a815e9b6-05fe-44a5-937f-458b03805d03.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-aems-e2br3-e2d-r1-icsr-submission-standards-2026</loc>
    <lastmod>2026-10-01T10:47:36+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Aems Accepts E2b(R3) Updates Aligned With Ich E2d Standards</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/368e3444-b9e2-426e-a12d-46d5495e093f.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-aems-e2b-r3-icsr-mandate-october-2026</loc>
    <lastmod>2026-10-01T10:44:08+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-01T00:00:00+05:30</news:publication_date>
      <news:title>FDA Mandates E2b Standard For All Icsr Submissions Via Aems Today</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/af13fdf1-f1e6-4f4b-86ca-4221b650544b.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ema-womens-health-regulatory-roadmap-q4-2026</loc>
    <lastmod>2026-10-01T15:15:35+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>EMA Sets Deadline for Women's Health Regulatory Roadmap After Amsterdam Workshop</news:title>
      <news:keywords>EMA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ema-womens-health-regulatory-roadmap-q4-202620261001151524.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-abbv-295-phase-1-amylin-analog-monthly-dosing-easd-2026</loc>
    <lastmod>2026-10-01T15:12:35+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Achieves Phase 1 Milestone for ABBV-295 Amylin Analog Supporting Monthly Dosing Intervals</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-abbv-295-phase-1-amylin-analog-easd-202620261001151229.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/roche-fda-priority-review-fenebrutinib-rms-ppms</loc>
    <lastmod>2026-09-30T13:41:56+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>Roche's Fenebrutinib Gets FDA Priority Review For RMS And PPMS</news:title>
      <news:keywords>Roche</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/5484c9ba-4f73-43ef-9a58-42efd650ec5a/19a67fd0-3ce6-4f3c-81a1-027aac7fc76a.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-zumilokibart-phase-2-apex-part-b-atopic-dermatitis-phase-3</loc>
    <lastmod>2026-10-01T15:11:35+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie's Zumilokibart Hits Phase 2 Endpoint For Atopic Dermatitis</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-zumilokibart-phase-2-apex-part-b-atopic-dermatitis-phase-320261001151123.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/astrazeneca-secures-stake-summit-therapeutics-2-billion-ivonescimab-deal</loc>
    <lastmod>2026-10-01T15:11:02+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>AstraZeneca Secures 12% Stake In Summit For $2B Ivonescimab Asset</news:title>
      <news:keywords>AstraZeneca</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/astrazeneca-summit-therapeutics-2-billion-ivonescimab-deal20261001150702.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lilly-foundayo-outperforms-oral-semaglutide-weight-loss-indirect-achieve-3-analysis</loc>
    <lastmod>2026-10-01T15:02:33+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>Lilly Foundayo Outperforms Oral Semaglutide In Weight Loss Trials</news:title>
      <news:keywords>Lilly</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-foundayo-oral-semaglutide-weight-loss-achieve-3-analysis20261001150221.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novo-nordisk-hengrui-oral-glp-1-deal-2-6-billion</loc>
    <lastmod>2026-10-01T14:55:03+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>Novo Nordisk Signs $2.6 Billion Deal with Hengrui for Oral GLP-1 Candidate</news:title>
      <news:keywords>Novo Nordisk</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novo-nordisk-hengrui-oral-glp-1-deal-2-6-billion20261001145357.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-crcg-lai-generics-workshop-december-2026-anda-submission</loc>
    <lastmod>2026-10-01T13:41:56+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>FDA &amp; CRCG Host December 2026 LAI Generics Workshop On ANDA Gaps</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-crcg-lai-generics-workshop-december-2026-anda-submission20261001134142.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-charges-indian-nationals-counterfeit-ozempic-distribution-scheme</loc>
    <lastmod>2026-10-01T13:36:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>FDA Charges Two Indian Nationals In Fake Ozempic Ring</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-charges-indian-nationals-counterfeit-ozempic-distribution-scheme20261001133630.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/telix-fda-fast-track-bipass-pre-biopsy-prostate-cancer-pet</loc>
    <lastmod>2026-10-01T13:34:32+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>Telix Secures FDA Fast Track For BiPASS Prostate Cancer Program</news:title>
      <news:keywords>Telix</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/telix-fda-fast-track-bipass-pre-biopsy-prostate-cancer-pet20261001133429.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/zealand-pharma-zupreme-1-phase-2-petrelintide-weight-loss-results</loc>
    <lastmod>2026-10-01T13:34:09+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>Zealand Petrelintide Hits Double Digit Weight Loss In Phase Two</news:title>
      <news:keywords>Zealand Pharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/zealand-pharma-zupreme-1-phase-2-petrelintide-weight-loss-results20261001133040.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/maat-pharma-chmp-rejection-xervyteg-fda-pre-ind-maat034-2026</loc>
    <lastmod>2026-10-01T13:29:51+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-30T00:00:00+05:30</news:publication_date>
      <news:title>MaaT Pharma Shifts MaaT034 To FDA Path After Xervyteg EU Rejection</news:title>
      <news:keywords>Maat Pharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/maat-pharma-chmp-rejection-xervyteg-fda-pre-ind-maat034-202620261001132425.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/medicus-pharma-submits-seamless-phase-2b3-protocol-fda-teverelix-advanced-prostate-cancer</loc>
    <lastmod>2026-09-30T12:00:47+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Medicus Pharma Submits Phase 2b/3 Teverelix Protocol to FDA</news:title>
      <news:keywords>Medicus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/medicus-pharma-fda-phase-2b3-teverelix-advanced-prostate-cancer20260930120033.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fresenius-kabi-fda-warning-letter-aseptic-processing-melrose-park-2026</loc>
    <lastmod>2026-09-30T11:59:07+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Fresenius Kabi Receives FDA Warning Letter After Aseptic Processing Investigation Failures at Melrose Park Facility</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fresenius-kabi-fda-warning-letter-aseptic-processing-melrose-park-202620260930115853.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/celmade-fda-warning-letter-unapproved-botulinum-toxin-2026</loc>
    <lastmod>2026-09-30T11:55:10+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Celmade Receives FDA Warning Letter for Unapproved Injectable Botulinum Toxin Sales into U.S.</news:title>
      <news:keywords>Celmade</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bentley-laboratories-fda-cgmp-warning-letter-202620260930115334.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/bentley-laboratories-fda-cgmp-warning-letter-2026</loc>
    <lastmod>2026-09-30T11:46:56+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Bentley Laboratories Receives FDA CGMP Warning Letter Citing OOS Investigation Failures and Unapproved Drugs</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bentley-laboratories-fda-cgmp-warning-letter-202620260930114651.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/akums-dcgi-approval-colchicine-cardiovascular-india-first</loc>
    <lastmod>2026-09-30T11:43:05+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Akums Gains DCGI Approval for Colchicine in Cardiovascular Indication, a First in India</news:title>
      <news:keywords>Akums</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/akums-dcgi-approval-colchicine-cardiovascular-india-first20260930114253.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/pfizer-45-oncology-studies-esmo-2025-madrid</loc>
    <lastmod>2026-09-30T11:36:14+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Pfizer Takes 45 Oncology Studies to ESMO 2025 Congress in Madrid Across Oral and Poster Sessions</news:title>
      <news:keywords>Pfizer</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/pfizer-45-oncology-studies-esmo-2025-madrid20260930113610.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-fda-approval-juvmo-parkinsons-disease-d1-d5-agonist</loc>
    <lastmod>2026-09-30T11:29:04+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Wins FDA Approval for JUVMO in Parkinson's Disease</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-fda-approval-juvmo-parkinsons-disease-d1-d5-agonist20260930112848.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/phathom-pharmaceuticals-initiates-phase-3-vonoprazan-as-needed-nerd</loc>
    <lastmod>2026-09-30T11:26:55+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Phathom Launches Phase 3 Vonoprazan Trial for GERD</news:title>
      <news:keywords>Phathom</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/phathom-pharmaceuticals-phase-3-vonoprazan-as-needed-nerd20260930112642.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/moleculin-biotech-completes-part-a-enrollment-miracle-trial-aml-q1-2027</loc>
    <lastmod>2026-09-30T11:24:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Moleculin Biotech Achieves Full Part A Enrollment in Phase 2/3 AML MIRACLE Trial</news:title>
      <news:keywords>Moleculin</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/moleculin-biotech-miracle-trial-aml-part-a-enrollment-q1-202720260930112438.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/epicur-pharma-fda-warning-letter-misbranded-compounded-animal-drugs-2026</loc>
    <lastmod>2026-09-30T11:20:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Epicur Pharma Receives FDA Warning Letter Over Misbranded Compounded Animal Drug Claims</news:title>
      <news:keywords>Epicur</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/epicur-pharma-fda-warning-letter-misbranded-compounded-animal-drugs-202620260930111955.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-signs-ai-collaboration-valkai-accelerate-clinical-development-timelines</loc>
    <lastmod>2026-09-30T11:18:00+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Partners With Valkai to Accelerate Clinical Development</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-valkai-ai-collaboration-clinical-development-timelines-202620260930111754.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/propanc-biopharma-gmp-manufacture-regulatory-phase-1b-prp-trial-2027</loc>
    <lastmod>2026-09-30T11:13:29+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Propanc Biopharma Advances GMP Manufacture and Regulatory Workstreams</news:title>
      <news:keywords>Propanc</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/propanc-biopharma-gmp-manufacture-regulatory-phase-1b-prp-trial-202720260930111320.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/newamsterdam-pharma-spinoza-trial-first-participant-preclinical-alzheimers</loc>
    <lastmod>2026-09-30T11:11:09+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial for Preclinical Alzheimer's Disease</news:title>
      <news:keywords>NewAmsterdam</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/newamsterdam-pharma-spinoza-trial-first-participant-preclinical-alzheimers20260930111101.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fibrobiologics-secures-european-patent-fibroblast-conditioning-spinal-disc-regeneration</loc>
    <lastmod>2026-09-30T11:03:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>FibroBiologics Secures European Patent for Fibroblast Conditioning Methods Covering Spinal Disc Regeneration</news:title>
      <news:keywords>FibroBiologics</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fibrobiologics-european-patent-fibroblast-conditioning-spinal-disc-regeneration20260930110248.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/kellin-chemicals-adulteration-designation-fda-inspection-refusal-zhangjiagang</loc>
    <lastmod>2026-09-30T10:58:18+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Kellin Chemicals Gains Adulteration Designation After Refusing FDA Facility Inspection in Zhangjiagang</news:title>
      <news:keywords>Kellin</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/kellin-chemicals-adulteration-designation-fda-inspection-refusal-zhangjiagang20260930105807.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/curia-new-york-fda-warning-letter-undocumented-chromatographic-injections-2026</loc>
    <lastmod>2026-09-30T10:54:48+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Curia New York Receives FDA Warning Letter Over Thousands of Undocumented Chromatographic Injections</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/curia-new-york-fda-warning-letter-undocumented-chromatographic-injections-202620260930105432.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ab-science-revises-clinical-trial-timelines-for-cause-gcp-inspection</loc>
    <lastmod>2026-09-29T18:44:13+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Ab Science Revises Trial Timelines After Three Gcp Inspections</news:title>
      <news:keywords>Ab Science</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ab-science-cause-gcp-inspection-clinical-trial-timelines-202620260929184005.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novo-nordisk-hengrui-pharma-license-hrs-1596-oral-glp1-gip-agonist</loc>
    <lastmod>2026-09-29T18:32:53+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Novo Nordisk Signs $2.6B Deal With Hengrui For Oral GLP-1</news:title>
      <news:keywords>Novo Nordisk</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novo-nordisk-hengrui-pharma-hrs-1596-oral-glp1-gip-agonist20260929183200.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/teva-fda-approval-degevma-denosumab-biosimilar-xgeva</loc>
    <lastmod>2026-09-29T18:25:52+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>Teva Wins FDA Nod For DEGEVMA, Completing Denosumab Portfolio</news:title>
      <news:keywords>Teva</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/teva-fda-approval-degevma-denosumab-biosimilar-xgeva20260929182504.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/boothwyn-pharmacy-fda-warning-letter-sterility-potency-failures-2026</loc>
    <lastmod>2026-09-29T18:21:52+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-29T00:00:00+05:30</news:publication_date>
      <news:title>FDA Warns Boothwyn Pharmacy Over Sterility, Potency Issues</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/boothwyn-pharmacy-fda-warning-letter-sterility-potency-failures-202620260929182105.webp</image:loc>
    </image:image>
  </url>
</urlset>